Company has been granted a patent protection from the Patent Office of the Republic of Poland for a set of primers amplifying Borrelia burgdorferi’s nucleotide sequence , i.e. the bacteria causing Lyme disease. The patent developed by the Genomtec team covers the method of detecting Borrelia burgdorferi, the method of Lyme disease diagnosis, and a diagnostic kit for Lyme disease. It is the second patent granted by the Patent Office of the Republic of Poland and the third patent received by the Company. Currently, Genomtec has got pending twenty patent applications worldwide.
The third patent owned by Genomtec increases company’s value for investors and confirms the innovativeness and uniqueness of the Genomtec ID solution, which among other infectious pathogens, will be able to detect now Lyme disease utilizing the patented technology. This is a particularly important achievement, because the diagnosis of Lyme disease is not easy due to non-specific systemic symptoms and varied clinical presentation, as well as issues with currently used laboratory diagnostic techniques – said Miron Tokarski, co-founder and CEO of Genomtec.
Genomtec ID will make possible to diagnose Lyme disease in several minutes during one medical appointment, including at the emergency department, in an ambulance or even in a pharmacy, providing a breakthrough diagnostics so much needed for an early intervention in diseased patients, who nowadays often must wait for many months for diagnostic confirmation, sometimes even leading to a spinal puncture to collect spinal fluid for examination.
The Company plans to manufacture several diagnostic panels, including one that will simultaneously diagnose Lyme disease, MRSA – methicillin-resistant staphylococcus aureus and the bacterial meningitis. These are very severe diseases, sometimes giving similar clinical symptoms, where proper and quick diagnosis initiates targeted treatment determining patient’s healthcare outcomes.
Patent protection of the technology or processes constituting the given technology is a key area of building and safeguarding the intellectual value developed by our Company. Genomtec’s technology is being ringfenced by securing ever-increasing number of patents and patent applications for the Genomtec ID diagnostic platform as well as in the space of molecular biology – CEO added.
